Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial

被引：0

作者：

Masip, J. Remon ^{[1
]}

Besse, B. ^{[1
]}

Aix, S. Ponce ^{[2
]}

Perez, A. Callejo ^{[3
]}

Al-Rabi, K. ^{[4
]}

Caro, R. Bernabe ^{[5
]}

Greillier, L. ^{[6
]}

Tarruella, M. Majem ^{[7
]}

Aransay, N. Reguart ^{[8
]}

Monnet, I. ^{[9
]}

Cousin, S. ^{[10
]}

Lopez, P. Garrido ^{[11
]}

Robinet, G. ^{[12
]}

Campelo, R. Garciaprime ^{[13
]}

Flandin, A-C. Madroszyk ^{[14
]}

Mazieres, J. ^{[15
]}

Curcio, H. ^{[16
]}

Pretzenbacher, Y. ^{[17
]}

Dingemans, A-M. C. ^{[18
]}

Dziadziuszko, R. ^{[19
]}

机构：

[1] Inst Gustave Roussy, Oncol Dept, Villejuif, France

[2] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[3] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[4] KHCC King Hussein Canc Ctr, Med Oncol & Hematol Dept, Amman, Jordan

[5] Hosp Univ Virgen Rocio, Seville, Spain

[6] Hop St Marguerite Assistance Publ Hop Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[7] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[8] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

[9] Chi Creteil, Creteil, France

[10] Inst Bergonie, Early Phase Trials, Bordeaux, France

[11] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[12] CHRU Brest Hop Morvan, Brest, France

[13] CHUAC Complexo Hosp Univ A Coruna, La Coruna, Spain

[14] IPC Inst Paoli Calmettes, Marseille, France

[15] Ctr Hosp Univ Toulouse, Thorac Oncol Dept, Hop Larrey, Toulouse, France

[16] Ctr Francois Baclesse, Oncol Dept, Caen, France

[17] EORTC AISBL IVZW European Org Res & Treatment Can, Stat, Brussels, Belgium

[18] Erasmus MC Univ, Pulmonol Dept, Med Ctr, Rotterdam, Netherlands

[19] Med Univ Gdansk, Oncol & Radiotherapy Dept, Gdansk, Poland

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S35 / S35

页数：1

共 50 条

[41] Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
Kim, Chul
Roper, Nitin
Hoang, Chuong D.
Wisch, Laura
Connolly, Maureen
Chou, Hsien-Chao
Wei, Jun S.
Tyagi, Manoj
Cultraro, Constance
Xi, Liqiang
Waris, Maryam
Szabo, Eva
Padiernos, Emerson
Kesarwala, Aparna Hemant
Gao, Shaojian
Steinberg, Seth M.
Raffeld, Mark
Rajan, Arun
Khan, Javed
Guha, Udayan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients
Uy, Natalie F.
Tratt, Micah
Eaton, Keith D.
Santana-Davila, Rafael
Baik, Christina S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Predictors of benefit to radiation for oligoprogressive disease in EGFR-mutant metastatic non-small cell lung cancer patients treated with osimertinib
Chen, Monica F.
Ma, Jennifer
Kris, Mark G.
Gomez, Daniel Richard
Yu, Helena Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44] Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients
Braune, E. -B.
Eide, I. J. Zwicky
Grundberg, O.
De Petris, L.
Brustugun, O. T.
Ekman, S.
Hydbring, P.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S623 - S623
[45] Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
Patil, Tejas
Pacheco, Jose M.
Dimou, Anastasios
Purcell, William T.
Rossi, Candice
Bunn, Paul A.
Doebele, Robert C.
Camidge, D. Ross
Ferrigno, Lisa
FRONTIERS IN ONCOLOGY, 2020, 10
[46] Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Ma, Y.
Zhao, H.
Zhao, Y.
Cheng, Y.
Cui, J.
Liu, G.
Xiong, D.
Zhang, J.
Xu, L.
Yu, J.
Men, L.
Liang, E.
Yang, D.
Zhang, L.
Zhai, Y.
ANNALS OF ONCOLOGY, 2023, 34
[47] Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
Lemmon, Christopher
Zabor, Emily Craig
Pennell, Nathan A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC).
Zhang, Li
Zhao, Hongyun
Zhao, Yanqiu
Cheng, Ying
Cui, Jiuwei
Ma, Yuxiang
Yang, Chen
Zhang, Jie
Xu, Liang
Yu, Juan
Men, Lichuang
Liang, Zhiyan
Yang, Dajun
Zhai, Yifan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
Paulina Bracht, Jillian Wilhelmina
Karachaliou, Niki
Berenguer, Jordi
Pedraz-Valdunciel, Carlos
Filipska, Martyna
Codony-Servat, Carles
Codony-Servat, Jordi
Rosell, Rafael
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
[50] Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
Wen, Lei
Zhen, Junjie
Shan, Changguo
Lai, Mingyao
Hong, Weiping
Wang, Hui
Ye, Mingting
Yang, Yanying
Li, Shaoqun
Zhou, Zhaoming
Zhou, Jiangfen
Hu, Qingjun
Li, Juan
Tian, Xuwei
Chen, Longhua
Cai, Linbo
Xie, Zhanhong
Zhou, Cheng
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)

← 1 2 3 4 5 →